-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Sector Analysis
Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Overview PIDs, also known as inborn errors of immunity (IEI), are a group of more than 400 rare, chronic conditions. In this part of the body’s immune system is either missing or does not function correctly. Any component of the immune system—cells, proteins (immunoglobulins), enzymes involved in immune regulation—may be at defect causing PID. These conditions are caused by hereditary genetic defects and can affect anyone, regardless of age, gender, or ethnicity....
-
Sector Analysis
von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032
von Willebrand Disease (vWD) Market Report Overview The von Willebrand Disease (vWD) market size in the three major markets (3MM) (US, Germany, and UK) was $892 million in 2022. The vWD market will register a CAGR of more than 8% from 2022 to 2032. The vWD market research report offers an overview of vWD, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications...
-
Product Insights
Kedrion – Tashkent Blood Plasma Plant – Toshkent Shahri
Equip yourself with the essential tools needed to make informed and profitable decisions with our Kedrion - Tashkent Blood Plasma Plant - Toshkent Shahri report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Product Insights
Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Primary immunodeficiency is defined as a weakened immune system that results in repeated infections and other health problems occurring more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Immune Deficiency, complete with analysis by stage of development, drug target, mechanism...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Product Insights
Polyradiculoneuropathy Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Polyradiculoneuropathy Global Clinical Trials Review, H1, 2018" provides an overview of Polyradiculoneuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Polyradiculoneuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...